阿托伐他汀调脂治疗对冠心病合并代谢综合征患者血脂水平及心脑血管事件发生率的影响分析  

Effect of Atto Vastatin on Blood Lipid Level and Incidence of Cardiovascular and Cerebrovascular Events in Patients with Coronary Heart Disease Complicated with Metabolic Syndrome

作　　者：赵晓雁 ZHAO Xiao-yan(Department of Pharmacy,Luoyang New District People＇s Hospital,Luoyang Henan 471023,China)

机构地区：[1]洛阳新区人民医院药剂科,河南洛阳471023

出　　处：《药品评价》2018年第21期14-16,20,共4页Drug Evaluation

基　　金：河南省科技攻关项目(编号:200803046)

摘　　要：目的:分析阿托伐他汀调脂治疗对冠心病合并代谢综合征患者血脂水平及心脑血管事件发生率的影响。方法:选取2017年1月至2018年5月期间在洛阳新区人民医院进行治疗的冠心病合并代谢综合征患者37例作为观察组,同时期入院治疗的37例单纯冠心病血脂异常患者作为对照组,两组患者在入院后均采用阿托伐他汀调脂治疗,对比两组患者治疗有效率、血脂指标以及心脑血管事件发生率。结果:观察组患者药物使用后的整体治疗有效率(72.97%)显著低于对照组(94.59%),观察组在药物服用后血脂水平与对照组比较,整体效果均较差,观察组患者心脑血管事件发生率(40.54%)与对照组(18.92%)比较,整体发生率较高,P<0.05。结论:冠心病合并代谢综合征采用阿托伐他汀调脂治疗,与单纯冠心病患者比较,治疗有效率较低,后期发生心脑血管疾病可能性更高,药物服用后,临床应用价值需进一步研究。Objective To analyze the effect of Atto vastatin on blood lipid level and incidence of cardiovascular and cerebrovascular events in patients with coronary heart disease complicated with metabolic syndrome. Methods： From January 2017 to May 2018, 37 patients with coronary heart disease complicated with metabolic syndrome were selected as observation group and 37 patients with simple coronary heart disease with dyslipidemia as control group. Two groups of patients were treated with Atto vastatin after admission. The effective rate, blood lipid index and incidence of cardiovascular and cerebrovascular events were compared between the two groups. Results： The overall effective rate after drug use in the observation group was 72.97%, which was significantly lower than that of the control group （94.59%）. The blood lipid level in the observation group was worse than that in the control group. The incidence of cardiovascular and cerebrovascular events in the observation group was 40.54% compared with 18.92% in the control group, and the overall incidence was higher than that in the control group （P〈0.05）. Conclusion： Coronary heart disease complicated with metabolic syndrome can be treated with Atto vastatin and lipid-regulating therapy. Compared with patients with coronary heart disease alone, the effective rate of treatment is lower; the possibility of cardiovascular and cerebrovascular diseases in later stage is higher. The value of clinical application needs further study.

关 键 词：阿托伐他汀调脂 冠心病合并代谢综合征 血脂水平 心脑血管事件发生率 

分 类 号：R972[医药卫生—药品]